The growth of the market is attributed to the growing prevalence of urinary tract infections, aging population, and emerging computing technologies for urine diagnostics. However, the lack of product awareness in emerging countries and effects associated with medication obstruct the growth of the Urinary Tract Infection Treatment market to a certain extent.
Based on drug class, the quinolones segment held the largest share of the market in 2019; however, the penicillin and combination segment is anticipated to register the highest CAGR of 4.5% in the market during the forecast period. The future growth of the market for quinolones is mainly ascribed to the fact that it is most commonly prescribed by physicians. Ciprofloxacin, levofloxacin, and enoxacin are among the most widely used drugs for treatment..
Get sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00005931/
- Teva Pharmaceutical Industries Ltd
- Sun Pharmaceutical Industries Ltd
- Mylan N.V.
- Pfizer Inc.
- Cipla Ltd
- F. Hoffmann-La Roche Ltd
- Shionogi Inc.
- DuPont Nutrition & Biosciences
Certain risk factors such as sexual activity, poor hygiene, and aging may cause UTIs. Increasing incidence of these risk factors are also estimated to drive the urinary tract infection treatment market growth by 2027. According to a study published in the International Journal of Environmental Research and Public Health in 2019, patients with existing chronic conditions such as coronary artery disease (CAD), chronic kidney disease (CKD), and diabetes mellitus (DM) have high possibilities of acquiring UTIs. Therefore, the high epidemiology of UTI generates demand for its treatment products, eventually driving the market growth.
Women are at a higher risk of developing urinary tract infections (UTIs) than men. UTIs, if go untreated, can lead to severe pain along with serious consequences to kidneys. UTIs show certain symptoms such as persistent urge to urinate, inflammation, change in appearance of urine, and nausea. The increasing prevalence of UTIs is one of the prominent factors driving the growth of the urinary tract infection treatment market. For instance, according to a study conducted by a group of researchers at the American College of Physicians and Infectious Diseases Society of America in 2020, UTIs accounts for ~6 million physicians visits each year in the US.
The urinary tract infection treatment market players—such as Shionogi & Co., Ltd.; Teva Pharmaceutical Industries Ltd; Allergan; and Pfizer—have been adopting several organic and inorganic strategies to enhance their revenue and market standings. For instance, in April 2019, Teva Pharmaceutical Industries Ltd announced the launch of a generic version of VESIcare (solifenacin succinate) Tablets, 5 mg and 10 mg, in the US.
Urinary Tract Infection Treatment Market– by Drug Class
Penicillin and Combinations
Urinary Tract Infection Treatment Market– by Indication
Complicated Urinary Tract Infection
Uncomplicated Urinary Tract Infection
Urinary Tract Infection Treatment Market– by Distribution Channel
Gynaecology and Urology Clinics
Retail Pharmacies and Drug Store
Online Drug Stores
Purchase This Report at: https://www.theinsightpartners.com/buy/TIPRE00005931/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.
Email: [email protected]
The Insight Partners
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.